News and innovations published by German exhibitorsback to overview
Since 2019 Bicoll GmbH has supported Galyan Bio Inc. in developing and optimizing an orally available small molecule for Huntington’s Disease Target. Clinical trials are scheduled for 2022.
Planegg / Martinsried (Germany) – Bicoll, an expert in synthesizing new and relevant small molecules as starting points for accelerated drug development, announced today its supporting role in the development of novel drug candidates for Huntington’s disease in collaboration with Galyan Bio.
Exhibitor: Bicoll GmbH